Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JTT-662 in Type 2 Diabetes on Metformin
NCT04465877Phase 1Completed
- Sponsor
- Akros Pharma Inc.
- Start
- Jun 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of JTT-662 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Akros Pharma Inc. Primary endpoints: Number of Subjects With Treatment-emergent Adverse Events at 6 Weeks, Number of Stools and Type of Stools Based on Bristol Stool Chart at 7 Weeks and 2 more. Started Jun 2020; status: completed.
02
Drugs
JTT-662
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04465877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04465877.